2-Apr-2026
No deal yet? Trump readies new tariffs on select drugmakers - report
Seeking Alpha News (Thu, 2-Apr 1:01 AM ET)
Lilly CEO says company opposes codification of Trump drug pricing deals
Seeking Alpha News (Wed, 1-Apr 5:16 PM ET)
Sanofi (SNYNF) Gets a Hold from Kepler Capital
TipRanks (Tue, 31-Mar 9:37 PM ET)
Sanofi Builds Immunology Momentum with March 2026 Wave of Global Approvals and Data
TipRanks (Tue, 31-Mar 5:26 PM ET)
Is Trump to blame for delayed drug launches in Europe
Seeking Alpha News (Tue, 31-Mar 12:28 PM ET)
TipRanks (Tue, 31-Mar 9:50 AM ET)
Sanofi unveils late-breaking phase 3 amlitelimab data in atopic dermatitis
Seeking Alpha News (Mon, 30-Mar 6:21 AM ET)
J.P. Morgan Sticks to Their Hold Rating for Sanofi (SNYNF)
TipRanks (Mon, 30-Mar 1:56 AM ET)
Sanofi announces leadership evolution in Specialty Care Business Unit
PRNewswire (Tue, 17-Feb 8:30 AM ET)
Sanofi’s $470M Vigil Neuroscience Deal Underscores 2025’s Record Year for Biotech Innovation
Market Chameleon (Tue, 18-Nov 2:10 AM ET)
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Sanofi - American Depositary Shares trades on the NASDAQ stock market under the symbol SNY.
As of April 2, 2026, SNY stock price climbed to $47.89 with 1,358,008 million shares trading.
SNY has a beta of 0.78, meaning it tends to be less sensitive to market movements. SNY has a correlation of 0.21 to the broad based SPY ETF.
SNY has a market cap of $115.23 billion. This is considered a Large Cap stock.
Last quarter Sanofi - American Depositary Shares reported $13 billion in Revenue and $.89 earnings per share. This fell short of revenue expectation by $-251 million and exceeded earnings estimates by $.05.
In the last 3 years, SNY traded as high as $60.12 and as low as $42.63.
The top ETF exchange traded funds that SNY belongs to (by Net Assets): PVAL, PPH, FVD, FENI, AVDE.
SNY has underperformed the market in the last year with a return of -7.8%, while SPY returned +18.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SNY shares. However, SNY has outperformed the market in the last 3 month and 2 week periods, returning -1.2% and +9.6%, while SPY returned -3.6% and -0.6%, respectively. This indicates SNY has been having a stronger performance recently.
SNY support price is $46.96 and resistance is $48.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNY shares will trade within this expected range on the day.